HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hypera Strikes Takeda Deal To Dominate Brazil's OTC Market

Executive Summary

Brazil's Hypera is paying Takeda $0.8bn for a portfolio of brands which will make it the "undisputed leader" in the South American country's OTC market. 

You may also be interested in...

LATAM Q1 Sales: Mexico's Genomma And Brazil's Hypera Report Gains

Genomma Lab reports OTC sales rise in Q1 thanks to gains in its LATAM region, while Brazil's Hypera posts big jump in turnover due to acquisitions. 

Top 20 Consumer Health Deals 2020: Private Equity And OTC Exits Drive M&A

HBW Insight reveals the biggest consumer health deals of 2020, and identifies growing private equity investment, portfolio streamlining by major players and pharma firms exiting OTC as the major drivers of M&A activity.

Takeda Divests Europe OTCs In $670m Deal As Rumors Swirl Of Japan Biz Sale

Takeda will divest a portfolio containing OTC drugs and dietary supplements to Denmark's Orifarm, while rumors suggest the company is poised to offload its substantial Japanese consumer healthcare business.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts